# An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.

> **NCT00301574** · PHASE3 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 398 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** galantamine

## Key facts

- **NCT ID:** NCT00301574
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-04
- **Primary completion:** —
- **Final completion:** 2004-02
- **Target enrollment:** 398 (ACTUAL)
- **Last updated:** 2011-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00301574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00301574, "An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00301574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*